Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb has expanded its strategic partnership with China-based Simcere Pharmaceutical Group to co-develop BMS-795311, Bristol-Myers' preclinical small molecule inhibitor of the Cholesteryl Ester Transfer Protein (CETP).
Subscribe to our email newsletter
CETP inhibition is believed to potentially raise HDL (good cholesterol) levels and help prevent cardiovascular disease.
As per the deal, Simcere will receive exclusive rights to develop and commercialize BMS-795311 in China while Bristol-Myers Squibb will retain exclusive rights in all other markets.
The strengths of both the companies will help in the advancement of the delivery of clinical Phase IIa proof-of-concept.
The financial terms of the deal have not been disclosed.